Skip to main content

VectivBio Stock Forecast, Price & News

+1.08 (+8.51 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume36,012 shs
Average Volume81,824 shs
Market Capitalization$468.39 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VECT News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:VECT
Phone41 61 551 30 3
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$468.39 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.58 out of 5 stars

Medical Sector

451st out of 2,039 stocks

Biotechnology Industry

28th out of 157 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

VectivBio (NASDAQ:VECT) Frequently Asked Questions

Is VectivBio a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VectivBio stock.
View analyst ratings for VectivBio
or view top-rated stocks.

What stocks does MarketBeat like better than VectivBio?

Wall Street analysts have given VectivBio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VectivBio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for VECT?

4 Wall Street analysts have issued 1-year price targets for VectivBio's stock. Their forecasts range from $19.00 to $28.00. On average, they anticipate VectivBio's stock price to reach $23.67 in the next year. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for VectivBio
or view top-rated stocks among Wall Street analysts.

Who are VectivBio's key executives?

VectivBio's management team includes the following people:
  • Dr. Luca Santarelli M.D., Founder, CEO & Director (Age 52)
  • Ms. Claudia D'Augusta Ph.D., Chief Financial Officer (Age 51)
  • Dr. Alain Bernard Ph.D., Chief Technology Officer (Age 64)
  • Dr. Christian Meyer, Chief Devel. Officer (Age 54)
  • Mr. Kevin Harris, Chief Commercial Officer (Age 50)
  • Dr. Sarah Holland Ph.D., Chief Bus. Officer (Age 58)

Who are some of VectivBio's key competitors?

When did VectivBio IPO?

(VECT) raised $128 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is VectivBio's stock symbol?

VectivBio trades on the NASDAQ under the ticker symbol "VECT."

When does the company's quiet period expire?

VectivBio's quiet period expires on Wednesday, May 19th. VectivBio had issued 7,500,000 shares in its IPO on April 9th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of VectivBio?

Shares of VECT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VectivBio's stock price today?

One share of VECT stock can currently be purchased for approximately $13.77.

How much money does VectivBio make?

VectivBio has a market capitalization of $468.39 million.

What is VectivBio's official website?

The official website for VectivBio is

How can I contact VectivBio?

The company can be reached via phone at 41 61 551 30 3.

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.